Unjha Formulations Ltd

Unjha Formulations Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 5 August 2026, reflecting a complex interplay of technical, valuation, financial trend, and quality factors. Despite an attractive valuation and solid long-term returns, recent technical signals and flat quarterly financials have raised concerns among analysts, prompting a reassessment of the stock’s outlook.

Unjha Formulations Ltd., a Gujarat-based pharmaceutical company specialising in Isabgol (Psyllium) formulations, reported a marginal improvement in its Q1 FY27 results, posting a net profit of ₹0.16 crores, a modest recovery from the loss-making Q4 FY26. However, the company's performance remains marred by persistent volatility and declining year-on-year metrics, raising questions about its operational stability and growth trajectory.

Unjha Formulations Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, signalling a positive change in price attractiveness amid a challenging pharmaceuticals sector. This micro-cap stock’s recent performance and valuation metrics merit close attention from investors seeking value in the Pharmaceuticals & Biotechnology space.

With a decisive surge to Rs 29.5 on 30 Jul 2026, Unjha Formulations Ltd has reached a fresh 52-week high, marking a significant milestone in its price momentum. This rally comes after a sustained four-day gain, delivering a 23.9% return in that period and outpacing its sector by over 7% today alone.

With a decisive surge to Rs 28.76 on 29 Jul 2026, Unjha Formulations Ltd has reached a fresh 52-week high, propelled by a confluence of bullish technical indicators and sustained price momentum over recent sessions.

Unjha Formulations Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 8 July 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The pharmaceutical micro-cap’s recent price action and technical signals have improved, prompting a reassessment of its market stance, even as financial trends remain subdued and valuation metrics present a mixed picture.

A sharp decline of 12.36% today dragged Unjha Formulations Ltd to a fresh 52-week low of Rs 17.52, marking a significant setback after four consecutive days of gains. This drop comes amid a broader market rally, highlighting a stark divergence in the stock’s performance.

Unjha Formulations Ltd’s share price declined sharply on 17 Jun 2026, hitting a new 52-week low of Rs 17.55. This marks a significant drop for the pharmaceutical company amid a challenging market environment and deteriorating financial metrics.

Unjha Formulations Ltd has been downgraded from a Sell to a Strong Sell rating as of 1 June 2026, reflecting deteriorating technical indicators and persistent financial weaknesses. Despite a very attractive valuation, the company’s flat quarterly performance, operating losses, and bearish technical trends have compelled analysts to revise their outlook, signalling caution for investors in this pharmaceuticals micro-cap.

Unjha Formulations Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 25 May 2026, driven primarily by a shift in technical indicators despite ongoing challenges in financial performance and valuation metrics. This nuanced change reflects a complex interplay of quality, valuation, financial trends, and technical signals that investors should carefully consider.

Unjha Formulations Ltd., a Gujarat-based pharmaceutical company specialising in Isabgol (Psyllium) formulations, reported a troubling quarterly performance for Q4 FY26, posting a net loss of ₹0.74 crores despite revenue growth. The micro-cap company, with a market capitalisation of ₹9.00 crores, saw its stock decline 0.55% to ₹20.00 following the results announcement, reflecting investor concerns about deteriorating profitability and operational challenges that have plagued the company throughout the fiscal year.

Unjha Formulations Ltd has been downgraded from a Sell to a Strong Sell rating as of 7 May 2026, reflecting deteriorating technical indicators and underwhelming financial performance. The company’s micro-cap status, combined with a sharp decline in share price and weak debt servicing ability, has prompted a reassessment of its investment appeal across quality, valuation, financial trend, and technical parameters.

Unjha Formulations Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 April 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The micro-cap pharmaceutical company’s Mojo Score has improved to 31.0, reflecting a nuanced change in market sentiment and technical trends, even as financial performance remains flat and long-term fundamentals show weaknesses.

Unjha Formulations Ltd’s stock price declined sharply on 7 April 2026, hitting a new 52-week low of Rs.18.6. This marks a significant downturn for the pharmaceutical and biotechnology company, reflecting ongoing challenges in its market performance and valuation metrics.

Unjha Formulations Ltd’s stock price declined to a fresh 52-week low of Rs.18.99 on 2 April 2026, marking a significant drop amid broader market weakness and sectoral pressures. The stock has been underperforming, reflecting a combination of company-specific factors and challenging market conditions.